Gocovri (amantadine) Price, Side Effects, Dosing, And Prescribing Information For Dyskinesia | Ravikesh Kumar, PharmD Intern | RxEconsult
Menus

All Health Articles

Gocovri (amantadine) Price, Side Effects, Dosing, And Prescribing Information For Dyskinesia Category: Neurology: Alzheimer's, Dementia, Development by - February 2, 2018 | Views: 2955 | Likes: 0 | Comment: 0  

Gocovri for dyskinesia

Brand Name: Gocovri
Generic Name: amantadine
Medication Class: NMDA Receptor Antagonist
Manufacturer: Adamas Pharma
FDA Approval Date: August 24, 2017

What is Gocovri and its mechanism of action?

Gocovri is an extended-release version of amantadine. How amantadine reduces dyskinesia in people with Parkinson’s disease is unknown. Amantadine is known to increase the effects of dopamine by acting on dopamine neurons. Amantadine also mimics the effect of drugs that block the action of acetylcholine.  

What is Gocovri used for treating?

Gocovri is used for the treatment of dyskinesia in people with Parkinson’s disease who are treated with levodopa, with or without dopaminergic medications. Dyskinesia is an the abnormal and/or uncontrolled involuntary movement of the body. Dyskinesia is a side effect of Levodopa treatment and it has a significant impact on activities of daily living.

Additionally, with the extended-release formulation, the “OFF” time of the drug is significantly decreased, causing less rebound dyskinesia symptoms.

What is the recommended dosing for Gocovri?

Gocovri comes in either 68.5 mg or 137 mg extended-release capsules. The capsule should be taken at bedtime and only needs to be taken once a day since it is an extended-release capsule.

The initial recommended dosing is 137 mg once daily. The dose should be increased to 274 mg once daily at bedtime after one week. The capsule should be swallowed whole but may be sprinkled on soft food. It may be taken with or without food. 

How effective is Gocovri?

The efficacy of Gocovri was tested in two randomized, double-blind, placebo-controlled studies that compared changes in the total United Dyskinesia Rating Scale (UDysRS) score. UDysRS is a rating scale that measures dyskinesia symptoms. The average UDysRS score after 12 weeks was compared to the average UDysRS scale score at the beginning of the study.

At the end of both studies, the UDysRS score was significantly decreased after 12 weeks of treatment. Additionally, there was significantly less troublesome dyskinesia, due to more “ON” time with the extended-release capsules.

What are the side effects of Gocovri?

  • Dry mouth
  • Urinary retention
  • Constipation
  • Hallucinations
  • Dizziness
  • Suicidal thought
  • Confusion
  • Orthostatic hypotension 

What are Gocovri’s drug interactions?

Taking Gocovri with other drugs that also block the effect of acetylcholine increases side effects such as dry mouth, urinary retention, and constipation. Example of these drugs includes ipratropium, atropine, and benztropine.

Carbonic anhydrase inhibitors, sodium bicarbonate, and other drugs that lower the urine pH should be avoided because they decrease the excretion of amantadine and may increase it blood levels and the chance of side effects.

Amantadine alters the effect of live attenuated influenza vaccines.

Combining amantadine with alcohol increases the chance of developing dizziness, confusion, and orthostatic hypotension.

What is the price of Gocovri?

The price of Gocovri is around $2,488 for 60 capsules, which is a 60-day supply. 

References

FDA approved prescribing information for Gocovri. 


For More Healthcare Insights Join Us On Twitter
and Facebook. Join The Community To Publish Articles.

Copyright 2018 RxEconsult. All Rights Reserved | Privacy Policy | Terms of Use | Sitemap